Physician profile
Indira Sofia Reyes-Contin
NPI 1093115081
$4,110.12
in general payments reported to CMS, 2019-2025
26 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $280 · 2021: $248 · 2022: $130 · 2023: $979 · 2024: $1,112 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $893.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $739.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $428.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $321.38 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.16 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Esperion Therapeutics, INC. | $191.73 | 2020-2021 | |
| Abbott Laboratories | $170.90 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $164.34 | 2020-2024 | |
| Exact Sciences Corporation | $160.32 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $156.35 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $150.45 | 2020-2025 | Shingrix, Arexvy |
| Cranial Technologies, INC | $97.91 | 2022-2025 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $68.83 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.43 | 2021 | |
| Merck Sharp & Dohme LLC | $58.85 | 2020-2023 | Pneumovax 23, Vaxelis, Vaxneuvance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $48.04 | 2021 | |
| Currax Pharmaceuticals LLC | $30.64 | 2024-2025 | Contrave |
| Inspire Medical Systems, INC. | $30.52 | 2025 | Inspire |
| Viiv Healthcare Company | $25.27 | 2025 | Apretude |
| Sanofi-Aventis U.S. LLC | $21.52 | 2025 | |
| Amgen INC. | $21.25 | 2020 | |
| Medtronic, INC. | $17.74 | 2025 | Venaseal |
| Allergan, INC. | $15.71 | 2020 | |
| Phadia US INC. | $14.73 | 2025 | Immunocap |
| Genentech USA, INC. | $14.24 | 2020 | |
| Ibsa Pharma INC. | $13.34 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Reyes-Contin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.